Previous 10 | Next 10 |
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 A...
The following slide deck was published by CinCor Pharma, Inc. in conjunction with this event. For further details see: CinCor Pharma (CINC) Investor Presentation - Slideshow
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the UBS 2022 Global Healthcare Conferen...
CinCor Pharma press release (NASDAQ:CINC): Q1 GAAP EPS of -$0.50. Cash, cash equivalents and marketable securities were $314.2 million as of March 31, 2022, as compared to $136.6 million as of December 31, 2021. For further details see: CinCor Pharma GAAP EPS of -$0.50
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial ev...
CinCor (CINC) stock rallied 15% on Monday, with the stock having risen 29% over the last five sessions. Shares of CINC opened at $21.99 and climbed steadily during morning trading. The stock recently changed hands at $24.99, up 15%, at approximately 1:40 p.m. CINC held its initial publi...
WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will participate in one-on-one...
CINC's single asset is CIN-107 targeting hypertension. The company is well-funded after a solid IPO. A number of data catalysts will happen in 2022. For further details see: CinCor: 2022 Data Catalysts Will Derisk The Stock
CinCor Pharma press release (NASDAQ:CINC): Q4 GAAP EPS of -$15.71. Ended 2021 with approximately $136.6 million in cash and cash equivalents. Shares +0.74%. For further details see: CinCor Pharma GAAP EPS of -$15.71
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer ...
News, Short Squeeze, Breakout and More Instantly...
CinCor Pharma Inc. Company Name:
CINC Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat ...
NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Oak Street Health, Inc. (NYSE:...
NEW YORK, NY / ACCESSWIRE / January 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ:CINC)'...